Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
List view / Grid view
Filter the results
The FDA has approved Tivicay (dolutegravir) and Tivicay PD (dolutegravir) dispersible tablets to treat HIV in children at least four weeks old and weighing at least 3kg.
A novel formulation for dolutegravir has been developed to improve HIV treatment options for children. Dr Kimberly Smith from ViiV Healthcare discusses the benefits of this new dispersible tablet.